Sigal Medical Lab Offers BCR-ABL Molecular Testing

Sigal Medical Lab is pleased to announce the availability of BCR-ABL molecular testing, an essential diagnostic and monitoring tool in the management of chronic myeloid leukemia (CML) and selected cases of acute lymphoblastic leukemia (ALL).

The BCR-ABL fusion gene, resulting from the Philadelphia chromosome translocation (t(9;22)), is a key molecular marker used for:

• Confirmation of CML diagnosis

• Baseline disease assessment

• Monitoring response to tyrosine kinase inhibitor (TKI) therapy

• Detection of minimal residual disease (MRD)

Testing is performed using advanced molecular techniques in accordance with international laboratory standards, ensuring high sensitivity, accuracy, and reproducibility of results.

By introducing BCR-ABL testing, Sigal Medical Lab strengthens its molecular diagnostics services, enabling clinicians to make timely, evidence-based treatment decisions and improving patient outcomes.

Sigal Medical Lab – Precision Diagnostics for Better Care.